PE Tech Report


Like this article?

Sign up to our free newsletter

Nordic Capital invests in ArisGlobalAs

Nordic Capital, a private equity investor with a resolute commitment to creating stronger, sustainable businesses, has further invested in ArisGlobal, by acquiring an additional shareholding from the founding Abbhi family.  

The transaction follows Nordic Capital’s initial investment in ArisGlobal, a provider of innovative software-as-a-service (SaaS) solutions for the life sciences industry in 2019 and subsequent years of significant growth for the Miami-based company. Drawing on its deep understanding of both the healthcare and technology sectors, Nordic Capital will continue to support ArisGlobal’s growth, with further investment into research and development, cognitive computing, global delivery and commercial operations.  

ArisGlobal is pioneering innovations to elevate life sciences and benefit humankind. The Company is on a mission to build an intuitive, intelligent, and unified software platform that enables the world’s best life sciences companies to bring safer products to market more quickly. Currently, more than 300 life sciences companies and government health authorities, including 30 of the top 50 global biopharmaceutical companies and the FDA, rely on ArisGlobal’s solutions to maintain regulatory compliance, manage and mitigate risk, and improve operational efficiency across the life sciences product lifecycle.  

With this further commitment from Nordic Capital, ArisGlobal will prioritise innovation and automation within its Clinical Development and Regulatory Affairs portfolios, with significant investments made across talent, technology, and customer experience. The funding will also fuel advancements to ArisGlobal’s market-leading capabilities in Drug Safety and Medical Affairs, where the Company has been recognized for being first in the industry to deliver cloud applications powered by cognitive computing. 

“This is an exciting day in the history of ArisGlobal,” says Sankesh Abbhi, President and CEO of ArisGlobal. “Since we began our partnership with Nordic Capital in 2019, we have shared a common vision for the future of the life sciences industry and I am proud to say that we have made great strides working together to realise that vision. We are committed to continuing to build intuitive, intelligent, and unified life sciences software that fundamentally transforms global health and improves the lives of patients. I have never been more enthusiastic and optimistic about our future.”  

Following the transaction, Sankesh Abbhi will, as President and CEO, remain a minority owner in ArisGlobal.  

“We are excited about the opportunity for Nordic Capital to show further commitment to ArisGlobal and support the growth and development of the company in partnership with the management team. ArisGlobal is transforming how most successful life sciences companies handle drug safety, clinical development, regulatory compliance, and medical affairs and this investment will further accelerate ArisGlobal’s growth in new product domains,” says Daniel Berglund, Partner, Nordic Capital Advisors and Member of ArisGlobal’s Board of Directors. 

Since inception in 1989, Nordic Capital has made 30 healthcare platform investments across Europe and North America and 19 investments in the Technology & Payments sector, supporting active value creation agendas to build industry winners. Recent investments in the US include ERT, a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development, and Cytel, a global provider of clinical trial design SaaS software, biometric services and advanced analytics. 

Like this article? Sign up to our free newsletter